Drugs / PROTHERACYTES
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04198883 | Nov 2018 → Jun 2020 | acute myocardial infarction | CellProthera | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02669810 | Feb 2016 → Mar 2024 | acute myocardial infarction | CellProthera | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-07-02 | CellProthera | Results Technology Networks: Could Regenerative Medicine Reverse Damage After a Heart Attack? cellprothera.com ↗
A cell therapy approach improved patients’ quality of life after a heartattack; plans for Phase 3 trials are underway. |
| 2025-09-25 | CellProthera | Results CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction cellprothera.com ↗
Treated patients showed a 9% average reduction in left ventricular end-systolic volume index, a reduction by half of severely damaged heart tissue at six months and a 70% average drop in NT-proBNP levels at three months. |
| 2025-06-30 | CellProthera | Results CellProthera Collaborator Presents Phase 1/2b Quality-of-Life Results for ProtheraCytes® Cell Therapy at ISTH cellprothera.com ↗
The poster presentation will show that patients’ physical and social functioning were significantly improved for patients who received ProtheraCytes®. |
| 2025-05-02 | CellProthera | Results CellProthera to Present ProtheraCytes® Clinical Data and Receive a Stem Cell Engineering Abstract Award for Phase I/IIb Results at ISCT 2025 Scientific Annual Meeting in New Orleans cellprothera.com ↗
The trial reported positive safety and efficacy data in patients following severe acute myocardial infarction, demonstrating the potential for ProtheraCytes to repair and regenerate heart tissue in this group. |
| 2024-07-12 | CellProthera | Results CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes© for the Treatment of Acute Myocardial Infarction cellprothera.com ↗
The ProtheraCytes, which are autologous, expanded CD34+ stem cells, were well tolerated with no unexpected serious adverse events reported. |
| 2024-07-11 | CellProthera | Results CellProthera and BioCardia Collaborate on Phase 2 Trial of ProtheraCytes to Treat AMI cellprothera.com ↗ |
| 2024-06-13 | CellProthera | Results Drug Development & Delivery: CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction cellprothera.com ↗
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. |
| 2024-05-14 | CellProthera | Results CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction cellprothera.com ↗ |
All press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Protheracytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04198883 ↗ |
| Modality | Cell therapy | “cell-based therapy” PMID 37952030 ↗ Nov 2023 |
| Route | Other | “intracardiac injection” NCT02669810 ↗ |